In the latest trading session,, 17.31 million Macrogenics Inc (NASDAQ:MGNX) shares changed hands as the company’s beta touched 1.64. With the company’s most recent per share price at $2.00 changing hands around $0.36 or 22.24% at last look, the market valuation stands at $126.49M. MGNX’s current price is a discount, trading about -188.5% off its 52-week high of $5.77. The share price had its 52-week low at $0.99, which suggests the last value was 50.5% up since then. When we look at Macrogenics Inc’s average trading volume, we note the 10-day average is 0.52 million shares, with the 3-month average coming to 672.59K.
Analysts gave the Macrogenics Inc (MGNX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.57. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended MGNX as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.
Macrogenics Inc (NASDAQ:MGNX) trade information
Instantly MGNX is in green as seen in intraday trades today. With action 32.77%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -38.31%, with the 5-day performance at 32.77% in the green. However, in the 30-day time frame, Macrogenics Inc (NASDAQ:MGNX) is 40.20% up. Looking at the short shares, we see there were 6.09 million shares sold at short interest cover period of 10.76 days.
The consensus price target for the stock as assigned by Wall Street analysts is 2.5, meaning bulls need an upside of 20.0% from its recent market value. According to analyst projections, MGNX’s forecast low is 2 with 3 as the target high. To hit the forecast high, the stock’s price needs a -50.0% plunge from its current level, while the stock would need to tank 0.0% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.47%. The 2025 estimates are for Macrogenics Inc earnings to decrease by -87.85%, but the outlook for the next 5-year period is at -23.54% per year.
MGNX Dividends
Macrogenics Inc is expected to release its next quarterly earnings report on 2025-May-12.
Macrogenics Inc (NASDAQ:MGNX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.01% of Macrogenics Inc shares while 89.59% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 92.38%. There are 89.59% institutions holding the Macrogenics Inc stock share, with BELLEVUE GROUP AG the top institutional holder. As of 2024-06-30, the company held 15.8662% of the shares, roughly 9.94 million MGNX shares worth $42.25 million.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 9.5749% or 6.0 million shares worth $25.5 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 2.82 shares estimated at $5.56 million under it, the former controlled 4.47% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 3.13% of the shares, roughly 1.97 shares worth around $3.89 million.
